



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ :

A01N 43/42

A1

(11) International Publication Number:

WO 90/14008

(43) International Publication Date:

29 November 1990 (29.11.90)

(21) International Application Number: PCT/US90/03065

(22) International Filing Date: 25 May 1990 (25.05.90)

(30) Priority data:

357,323

25 May 1989 (25.05.89)


US

(71) Applicant: SLOAN-KETTERING INSTITUTE FOR
CANCER RESEARCH [US/US]; 1275 York Avenue,
New York, NY 10021 (US).(72) Inventors: CHOU, Ting-Chao ; 304 East 65th Street, New
York, NY 10021 (US). WU, Tian-Shung ; 257 Hsi-Men
Road, Section 2, Tainan (CN).(74) Agent: WHITE, John, P.; Cooper & Dunham, 30 Rocke-
feller Plaza, New York, NY 10112 (US).(81) Designated States: AT (European patent), AU, BE (Euro-
pean patent), CA, CH (European patent), DE (Euro-
pean patent)*, DK (European patent), ES (European pa-
tent), FR (European patent), GB (European patent), IT
(European patent), JP, KR, LU (European patent), NL
(European patent), SE (European patent).


Published

With international search report.


(54) Title: METHODS AND COMPOSITIONS FOR INHIBITING TUMOR CELL GROWTH




(I)



(II)



(III)



(IV)

(57) Abstract

The subject invention discloses methods of inhibiting growth of tumor cells which comprise contacting the cells with a growth inhibiting amount of a compound having one of structures: (I), wherein R¹ is a hydroxyl or acetyl group; R² is hydrogen, -CH₂-CH=C(CH₃)₂ or a methoxy group; R³ is a hydroxyl, methoxy or acetyl group; R⁴ is hydrogen, -CH₂-CH=C(CH₃)₂ or a methoxy group; R⁵ is a hydroxyl, methoxy or acetyl group; R⁶ is hydrogen or a hydroxyl, methoxy or acetyl group; and R¹⁰ is a methyl group; (II), wherein R⁵ is hydrogen or -CH₂-CH=C(CH₃)₂; R⁶ is a hydroxyl group; R¹⁰ is hydrogen or a hydroxyl group; R¹¹ is a hydroxyl or methoxy group; and R¹² is hydrogen or a methyl group (III, IV). This invention also provides compositions for inhibiting growth of tumor cells which comprise one of the above-identified compounds and wherein the compound substituents comprise hydrophilic substituents to increase solubility.

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America


METHODS AND COMPOSITIONS FOR INHIBITING TUMOR CELL GROWTH

This application is a continuation-in-part of U.S. Serial No. 357,323, filed May 25, 1989, the contents of which are hereby incorporated by reference into the present disclosure.

The invention described herein was made in the course of work under Grant Nos. CA18856, CA27569 and AI26056 from the National Cancer Institute, U.S. Department of Health and Human Services. The U.S. Government may have certain rights in this invention.

Background of the Invention

A number of naturally occurring acridone alkaloids have been isolated from the family Rutaceae, but only acronycine (1) has been noted for its antitumor activity. (Throughout the specification, compounds will be cross-referenced with underlined numbers to facilitate reading and to avoid repetition of long chemical names).





Acronycine was isolated from the bark of the Australian scrub, Acronychi baueri Schott (Rutaceae) (Hughes, G.K., et al., Nature, 162:223-224 (1948); McDonald, P.L. and A.V. Robertson, Aust. J. Chem., 19:275-281 (1966); Svoboda, G.H., Lloydia, 29:206-224 (1966)). Experimental studies on acronycine in animals (Finkelstein, T.Z., et al. Cancer

Chemother. Reports, 59:975-983 (1975); Schneider, J., et al., J. Med. Chem., 15:266-270 (1972); Svoboda (1966); Svoboda, G.H., et al., J. Pharm. Sci., 55:758-768 (1966); Svoboda, G.H., U.S. Patent No. 3,985,899, issued October 12, 1976; Svoboda, G.H., U.S. Patent No. 4,309,431, issued January 5, 1982) showed it to be effective against a wide range of neoplasms. Because of its antitumor activity, it has undergone clinical trials (Division of Cancer Treatment, Program Statistics, March 30, 1970, Department HEW, Public Health Service, NIH, IND status filed for acronycine).

Acronycine was found to inhibit the incorporation of extracellular nucleosides into the DNA and RNA of cultured L5178Y cells, but did not interact with DNA (Dunn, B.P., et al. Cancer Res., 33:2310-2319 (1973)). The inhibitory effect of the alkaloid may be the result of an alteration in the transport of uridine through the plasma membrane instead of impaired nucleoside or nucleotide phosphorylation (Dunn, B.P., et al. Cancer Res., 33:2310-2319 (1973)). Similar mechanisms of action were also observed in other studies which indicated that the alkaloid acts primarily on membranous organelles, and its delayed effects may be in part due to interference with the structure, function, and/or turnover of cell-surface components (Tan, P., and N. Auersperg, Cancer Res., 33:2320-2329 (1973)).

Several derivatives of acridinone have been synthesized and tested for their antitumor activity (Liska, K.J., J. Med. Chem., 15:1177-1179 (1972); Radzikowski, C., et al. Arch. Immunol. Ther. Exp., 19:219-228 (1971); Reisch, J. and S.M.E. Aly, Arch. Pharm., 319:25-28 (1986); Schneider, J., et al. J. Med. Chem. 15:266-270 (1972); Svoboda, G.H. Lloydia 29:206-224 (1966)). Of those derivatives synthesized, only *O*-(dimethylaminoethyl)noracronycine (2) (Reisch, J. and S.M.E. Aly, Arch. Pharm. 319:25-28 (1986)) and 1-nitro-N¹⁰-substituted acridine-9-ones (3)

(Radzikowski, C., et al., Arch. Immunol. Ther. Exp. 19:219-228 (1971)), showed biological activity. Compound 2, bearing a charged dimethyl-aminoethyl side-chain, was reported to exhibit significant antitumor activity (Reisch, J. and S.M.E. Aly, Arch. Pharm. 319:25-28 (1986)). It is possible, therefore, that change of the overall molecular lipophilic-hydrophilic balance and electronic distribution caused by addition of a charged side-chain or nitro function on the molecule of acridine-9-one alter biological activity.




Svoboda, G.H., U.S. Patent Nos. 4,309,431 and 3,985,899, filed January 5, 1982 and October 12, 1976, respectively, teach a method of inhibiting growth of tumor cells using acronycine. However, they do not teach or suggest that other acridone alkaloids may be used to inhibit tumor growth.

To determine structure-activity relationships, the effects of 50 acridone alkaloids on the incorporation of the labeled precursors, [^3H -methyl]dThd, [$5\text{-}^3\text{H}$]Cyd and [$2,3,4,5\text{-}^3\text{H}$]L-Leu, into DNA, RNA and protein, respectively, were studied. The inhibition by these acridone alkaloids against human leukemic HL-60 cell growth was also studied.

Summary of the Invention


The subject invention discloses a method of inhibiting growth of tumor cells which comprises contacting the cells with a growth inhibiting amount of a compound having the structure:



15 wherein R^1 is a hydroxyl or acetyl group; R^2 is hydrogen, $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ or a methoxy group; R^3 is a hydroxyl, methoxy or acetyl group; R^4 is hydrogen, $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ or a methoxy group; R^5 is a hydroxyl, methoxy or acetyl group; R^6 is hydrogen or a hydroxyl, methoxy or acetyl group; and R^{10} is a methyl group.

20 A composition for inhibiting growth of tumor cells comprising an amount of the above-identified structure effective to inhibit growth of tumor cells and a physiologically acceptable carrier is also provided.

25 This invention also provides a method of inhibiting growth of tumor cells which comprises contacting the cells with a growth inhibiting amount of a compound having the structure:




35 wherein R^5 is hydrogen or $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^6 is a hydroxyl group; R^{10} is hydrogen or a hydroxyl group;

R^{11} is a hydroxyl or methoxy group; and R^{12} is hydrogen or a methyl group.


5 A composition for inhibiting growth of tumor cells comprising an amount of the above-identified structure effective to inhibit growth of tumor cells and a physiologically acceptable carrier is also provided.

10 The subject invention also discloses a method of inhibiting growth of tumor cells which comprises contacting the cells with a growth inhibiting amount of a compound having the structure:



20 Further provided is a composition comprising an amount of the above-identified compound effective to inhibit growth of tumor cells and a physiologically acceptable carrier.


25 The subject invention additionally discloses a method of inhibiting growth of tumor cells which comprises contacting the cells with a growth inhibiting amount of a compound having the structure:



35 Further provided is a composition comprising an amount of the above-identified compound effective to inhibit growth of tumor cells and a physiologically acceptable carrier.

Detailed Description of the Invention

The subject invention discloses a method of inhibiting growth of tumor cells which comprises contacting the cells with a growth inhibiting amount of a compound having the structure:




wherein R^1 is a hydroxyl or acetyl group; R^2 is hydrogen, $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ or a methoxy group; R^3 is a hydroxyl, methoxy or acetyl group; R^4 is hydrogen, $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ or a methoxy group; R^5 is a hydroxyl, methoxy or acetyl group; R^6 is hydrogen or a hydroxyl, methoxy or acetyl group; and R^{10} is a methyl group.

All methods disclosed in this application may be effected in vitro or in vivo. When these methods are performed in vivo, the administration of the compound may be effected by any of the well known methods, including but not limited to oral, intravenous, intramuscular, and subcutaneous. The method of delivery, the amount to be used, and the frequency of delivery are expected to vary according to the situations, the carrier used, and result desired. However, those variables are readily determinable by one skilled in the art.

In one compound of the preferred embodiment, R^1 is an acetyl group; R^2 is hydrogen; R^3 is a methoxy group; R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^5 is an acetyl group; and R^6 is hydrogen. This compound is O,O-diacetyl-glycocitrine-I (14).

5



O,O-Diacetyl- (14)
glycocitrine-I


10

In the first subgroup of the preferred embodiment, R^1 is a hydroxyl group and R^5 is a hydroxyl or a methoxy group.

15

In one preferred compound of the first subgroup, R^2 is hydrogen; R^3 is a methoxy group; R^4 is a methoxy group; R^5 is a hydroxyl group; and R^6 is hydrogen. This compound is citrusinine-I (16)

20




Citrusinine-I (16)

25

In another preferred compound of this subgroup, R^2 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^3 is a hydroxyl group; R^4 is hydrogen; R^5 is a methoxy group; and R^6 is a hydroxyl group. This compound is buntanine (25).

30




35

Buntanine (25)

The first subgroup may be further divided to a second subgroup wherein R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ or a methoxy group.


In one preferred compound of this second subgroup, R^2 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^3 is a hydroxyl group; R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^5 is a hydroxyl group; and R^6 is hydrogen. This compound is N-methyl-atalaphylline (26).



The second subgroup may be further divided to a third subgroup wherein R^2 is hydrogen or a methoxy group; and R^3 is a methoxy or acetyl group.

20

In one preferred compound of this subgroup, R^2 , R^3 , R^4 and R^5 are methoxy groups; and R^6 is a hydroxyl group. This compound is glyfoline (31):




The third subgroup may be further divided to a fourth subgroup wherein R^2 is hydrogen.

35

In one preferred compound of this subgroup, R^3 is a methoxy


group; R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^5 is a hydroxyl group; and R^6 is hydrogen. This compound is glycocitrine-I (13).



Glycocitrine-I (13)

The fourth subgroup maybe further divided to a fifth subgroup, wherein R^5 is a methoxy group.

In one preferred compound of this subgroup, R^3 is methoxy group; R^4 is a methoxy group; and R^6 is hydrogen. This compound is 5-O-methyl-citrusinine-I (17):




5-O-Methyl-citrusinine-I (17)

The fifth subgroup maybe further divided to a sixth subgroup, wherein R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; and R^6 is a hydroxyl, methoxy or acetyl group.

In one preferred compound of this subgroup, R^3 and R^6 are methoxy groups. This compound is grandisinine (29):

5

Grandisinine (29)


10

The sixth subgroup maybe further divided to a seventh subgroup, wherein R^6 is a methoxy or acetyl group.

15

In one preferred compound of this subgroup, R^3 is an acetyl group and R^4 is a methoxy group. This compound is 3,6-O,O-diacetyl-prenylcitpressine (28):


20

3,6-O,O-Diacetyl- (28)
prenylcitpressine

25


In another preferred compound of this subgroup, R^3 and R^4 are methoxy groups. This compound is balyumine-B (30):

30

Balyumine-B (30)

35

The subject invention also provides a composition for inhibiting growth of tumor cells which comprises an amount of the compound having the structure:




wherein R^1 is a hydroxyl or acetyl group; R^2 is hydrogen, $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ or a methoxy group; R^3 is a hydroxyl, methoxy or acetyl group; R^4 is hydrogen, $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ or a methoxy group; R^5 is a hydroxyl, methoxy or acetyl group; R^6 is hydrogen or a hydroxyl, methoxy or acetyl group; and R^{10} is a methyl group;

effective to inhibit growth of tumor cells and a physiologically acceptable carrier.

This invention also provides for the above-indicated compositions wherein the compound comprises hydrophilic substituents to increase solubility. Hydrophilic molecules which may be used as substituents are well known in the art. However, compositions comprising the disclosed compounds with hydrophilic substituents are previously unknown.


In one compound of the preferred embodiment, R^1 is an acetyl group; R^5 is hydrogen; R^3 is a methoxy group; R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^5 is an acetyl group; and R^6 is hydrogen. This compound is O,O-diacetyl-glycocitrine-I (14):



O,O-Diacetyl- (14)
glycocitrine-I


In the first subgroup of the preferred embodiment, R^1 is a hydroxyl group and R^5 is a hydroxyl or a methoxy group.

In one preferred compound of the first subgroup, R^2 is hydrogen; R^3 is a methoxy group; R^4 is a methoxy group; R^5 is a hydroxyl group; and R^6 is hydrogen. This compound is citrusinine-I (16):



Citrusinine-I (16)


In another preferred compound of this subgroup, R^2 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^3 is a hydroxyl group; R^4 is hydrogen; R^5 is a methoxy group; and R^6 is a hydroxyl group. This compound is buntanine (25):



Buntanine (25)


The first subgroup may be further divided to a second subgroup, wherein R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ or a methoxy group.

In one preferred compound of this second subgroup, R^2 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^3 is a hydroxyl group; R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^5 is a hydroxyl group; and R^6 is a hydrogen. This compound is N-methyl-atalaphylline (26):

N-Methyl-
atalaphylline (26)


The second subgroup maybe further divided to a third subgroup, wherein R^2 is hydrogen or a methoxy group; and R^3 is a methoxy or acetyl group.

In one preferred compound of this subgroup, R^2 , R^3 , R^4 and R^5 are methoxy groups; and R^6 is a hydroxyl group. This compound is glyfoline (31):

Glyfoline (31)

The third subgroup maybe further divided to a fourth subgroup wherein R^2 is hydrogen.


In one preferred compound of this subgroup, R^3 is a methoxy group; R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^5 is a hydroxyl group; and R^6 is hydrogen. This compound is glycocitrine-I (13):

Glycocitrine-I (13)

The fourth subgroup maybe further divided to a fifth subgroup, wherein R^5 is a methoxy group.

In one preferred compound of this subgroup, R^3 is a methoxy group; R^4 is a methoxy group; and R^6 is hydrogen. This compound is 5-O-methyl-citrusinine-I (17):

5



10

5-O-Methyl- (17)
citrusinine-I


15

The fifth subgroup maybe further divided to a sixth subgroup, wherein R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; and R^6 is a hydroxyl, methoxy or acetyl group.

20

In one preferred compound of this subgroup, R^3 and R^6 are methoxy groups. This compound is grandisinine (29):

25



Grandisinine (29)


30

The sixth subgroup maybe further divided to a seventh subgroup, wherein R^6 is a methoxy or acetyl group.

35

In one preferred compound of this subgroup, R^3 is an acetyl group and R^4 is a methoxy group. This compound is 3,6-O,O-diacetyl-prenylcitpressine (28):

5




3,6-O,O-Diacetyl- (28)
prenylcitpressine

10

In another preferred compound of this subgroup, R³ and R⁴ are methoxy groups. This compound is balyumine-B (30):

15



Balyumine-B (30)

20

25

Physiologically acceptable carriers, as discussed throughout the application, are to include any carrier compatible with life. The choice of carrier is readily determinable to one skilled in the art. The physiologically acceptable carrier encompasses any of the standard carriers such as sterile solution, tablets, coated tablets and capsules. Typically such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color additives or other ingredients. Compositions comprising

30

35

such carriers are formulated by well known conventional methods. However a composition comprising the compound of the subject invention effective to inhibit growth of tumor cells is previously unknown.


5

Any of the above-described compositions wherein the composition comprises an agent to increase solubility represent the preferred embodiment of the invention.

10 Agents to increase solubility, as used throughout the application, are to include, but are not limited to, compounds which react with the hydrophobic regions of the subject compounds. Some examples of suitable agents include Emulphor (a polyoxyethylenated fatty acid which is water
15 miscible and non-toxic when diluted 1:10 with either sterile water or sterile physiological saline solution) and polyvinylpyrrolidone. Both Emulphor and polyvinylpyrrolidone have been disclosed for use in administering acronycine by Svoboda, G.H. in U.S. patent
20 nos. 3,985,899, filed October 12, 1976, and 4,309,431, filed January 5, 1982. However, Svoboda does not teach or suggest the use of Emulphor or polyvinylpyrrolidone in the methods or compositions of the subject invention.

25 This invention also provides a method of inhibiting growth of tumor cells which comprises contacting the cells with a growth inhibiting amount of a compound having the structure:

30




wherein R^5 is hydrogen or $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^6 is a hydroxyl group; R^{10} is a hydrogen or a hydroxyl group; R^{11} is a hydroxyl or methoxy group; and R^{12} is a hydrogen or methyl group.

5

In a preferred compound of this embodiment, R^5 is hydrogen; R^{10} is a hydroxyl group; R^{11} is a methoxy group; and R^{12} is a methyl group. This compound is citracridone-I (42):

10



15


Citracridone-I (42)

20

The preferred embodiment may be divided to a first subgroup, wherein R^{10} is a hydrogen; and R^{11} is a hydroxyl group.

In a preferred compound of the first subgroup, R^5 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ and R^{12} is hydrogen. This compound is atalaphyllinine (40):

30




Atalaphyllinine (40)

35

The first subgroup may be divided to a second subgroup,


wherein R^5 is hydrogen.

In one preferred compound of the second subgroup, R^{12} is a methyl group. This compound is 11-hydroxy-noracronycine (37).




11-Hydroxy-nor- (37)
acronycine

In another preferred compound of the second subgroup, R^{12} is hydrogen. This compound is atalaphyllidine (34).



Atalaphyllidine (34)

The subjection invention further discloses a composition comprising an amount of a compound having the structure:



wherein R^5 is hydrogen or $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^6 is a hydroxyl group; R^{10} is a hydrogen or a hydroxyl group; R^{11} is a hydroxyl or methoxy group; and R^{12} is a hydrogen or methyl group;


effective to inhibit growth of tumor cells and a physiologically acceptable carrier.

This invention also provides for the above-indicated

compositions wherein the compound comprises hydrophilic substituents to increase solubility. Hydrophilic molecules which may be used as substituents are well known in the art. However, compositions comprising the disclosed compounds with hydrophilic substituents are previously unknown.

In the preferred embodiment, R^6 is a hydroxyl group; R^{10} is hydrogen or a hydroxyl group; and R^{11} is a hydroxyl or methoxy group.


In a preferred compound of this embodiment, R^5 is hydrogen; R^{10} is a hydroxyl group; R^{11} is a methoxy group; and R^{12} is a methyl group. This compound is citracridone-I (42):



Citracridone-I (42)

The preferred embodiment may be divided to a first subgroup, wherein R^{10} is a hydrogen; and R^{11} is a hydroxyl group.


In a preferred compound of the first subgroup, R^5 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ and R^{12} is hydrogen. This compound is atalaphyllinine (40):



Atalaphyllinine (40)


The first subgroup may be divided to a second subgroup, wherein R^5 is hydrogen.

5 In one preferred compound of the second subgroup, R^{12} is a methyl group. This compound is 11-hydroxy-noracronycine (37):



11-Hydroxy-nor- (37)
acronycine


15 In another preferred compound of the second subgroup, R^{12} is hydrogen. This compound is atalaphyllidine (34):



Atalaphyllidine (34)


20 In any of the above-defined compositions, wherein the composition comprises an agent to increase solubility, it is to be considered a preferred embodiment.

25 The subject invention also discloses a method of inhibiting growth of tumor cells which comprises contacting the cells with a growth inhibiting amount of a compound having the structure:



Pyranofoline (48)

Further provided is a composition comprising an amount a compound having the structure:




Pyranofoline (48)

effective to inhibit growth of tumor cells and a physiologically acceptable carrier.

This invention also provides for the above-indicated compositions wherein the compound comprises hydrophilic substituents to increase solubility. Hydrophilic molecules which may be used as substituents are well known in the art. However, compositions comprising the disclosed compounds with hydrophilic substituents are previously unknown.


In the preferred embodiment, the composition further comprises an agent to increase solubility.

Additionally, this invention discloses a method of inhibiting growth of tumor cells which comprises contacting the cells with a growth inhibiting amount of a compound having the structure:



Cycloglyco- (50)
foline

Also provided is a composition comprising an amount a compound having the structure:



Cycloglyco- (50)
foline

effective to inhibit growth of tumor cells and a physiologically acceptable carrier.

This invention also provides for the above-indicated compositions wherein the compound comprises hydrophilic substituents to increase solubility. Hydrophilic molecules which may be used as substituents are well known in the art. However, compositions comprising the disclosed compounds with hydrophilic substituents are previously unknown.

Lastly, the subject invention provides the above composition wherein the composition further comprises an agent to increase solubility.

- 5 The following Experimental Detail section and Examples are set forth to aid in an understanding of the invention. These sections are not intended to, and should not be construed to, limit in any way the invention as set forth the claims which follow thereafter.

Experimental Detail

5 All acridone alkaloids were either previously isolated from plants indigenous to Taiwan or were obtained by partial synthesis. The isolation and structure elucidation data for each compound are referenced in Tables 1-3.

10 The structures of compounds 4-10 have been disclosed by Wu, T.-S., Yakugaku Zasshi, 103:1103-1107 (1983); compounds 1, 11-14, 31, 33-35, 38, 39 and 48-51 have been disclosed by Wu, T.-S., J. Chem. Soc. Perkin Trans. I., 1681-1688 (1982); compounds 15-17 and 27 have been disclosed by Wu, T.-S. and H. Furukawa, Chem. Pharm. Bull., 31:901-906 (1983); compounds 19-21, 28, and 29 have been disclosed by Wu, T.-S., C.-S. Kuoh and H. Furukawa, Phytochemistry, 22:1493-1497 (1983); compounds 22, 23, 39 and 42-45 have been disclosed by Wu, T.-S., C.-S. Kuoh and H. Furukawa, Chem. Pharm. Bull., 31:895-900 (1983); compound 25 has been disclosed by Wu, T.-S., Phytochemistry; 27, in press. (1988); compounds 26, 32, 36, 41, 42, 46 and 47 have been disclosed by Wu, T.-S. Kuoh and H. Furakawa, Phytochemistry, 21:1771-1773 (1982); compound 30 has been disclosed by Wu, T.-S., Phytochemistry, 26:871-872 (1987); and compound 52 has been disclosed by Furukawa, H., T.-S. Wu, C.-S. Kuoh, T. Sato, Y. Nagai and K. Kagei, Chem. Pharm. Bull., 32:1647-1649 (1984).

30 For the precursor incorporation studies, each compound (in 0.3% dimethylsulfoxide) was preincubated with HL-60 cells (a human promyelocytic leukemic cell line) 2.2×10^6 /ml, for 15 min prior to the addition of the labeled precursor (obtained from ICN Radiochemicals, Irvine, CA) and then incubated for 30 min. The precursors used for incorporation into DNA, RNA and protein were [3 H-methyl]dThd (1 μ Ci, 0.15 nmole/ml), [5 - 3 H]Cyd (5 μ Ci, 0.23 nmol/ml), and [2,3,4,5- 3 H]L-Leu (0.5 μ Ci, 0.004 nmol/ml), respectively. Incorporation of radioactivity in the absence of a plant compound and in the

35

presence of dimethylsulfoxide was used as a control. The control values for incorporation into DNA, RNA and protein were 8,500, 5,600 and 1,700 cpm/ 10^6 cells, respectively. The incubation conditions and the procedures for isolating DNA, RNA and protein fractions have been previously described (Chou, T.-C., et al., Cancer Res., 43:3074-3079 (1983)).

For growth inhibition studies, HL-60 cells (1.5×10^5 /ml) were grown in RPMI 1640 media (GIBCO, Grand Island, NY) at 37°C in humidified 5% CO₂ for 72 h. Viable cells were determined using trypan blue exclusion and counted in a hemocytometer. The fractional inhibition for each compound concentration (0.0025-0.05 mg/ml in 0.1% dimethylsulfoxide) was analyzed with the median-effect plot using a computer program (Chou, T.-C and P. Talalay, Adv. Enzyme Regul., 22:27-55 (1984); Chou, J. and T.-C. Chou, Dose-Effect analysis with microcomputers: Quantitation of ED50, LD50, synergism, antagonism, low-dose risk, receptor ligand binding and enzyme kinetics. A computer software disk for Apple II series or IBM-PC and manual. Elsevier Science Publishers, Elsevier-BioSoft, Cambridge, United Kingdom (1986)). The median-effect concentration (IC₅₀) was determined automatically for three to five dose-effect levels. Cell growth in the absence of plant compound and in the presence of dimethylsulfoxide was used as a control. Dimethylsulfoxide alone inhibited cell growth $3.9\% \pm 1.5\%$ during the 72 h incubation period. Those data with negative values represent activations.

Results and Discussion


Effects of Acridine Alkaloids on Precursor Incorporation into Cellular DNA

Human promyelocytic cells (HL-60) were incubated with [³H-

methyl]dThd in the presence and absence of a plant alkaloid. The percentage of inhibition of precursor incorporation in to DNA was tested with compound concentration of 0.03 mg/ml.

- 5 Acridin-9-one derivatives (Table 1), which bear 1,3-di (4 and 5) and 1,3,10-tri-sustituents (6-10) showed no significant activity on the inhibition of DNA synthesis with the exception of compound 10 which exhibited excellent inhibitory effect by inhibiting over 90% of DNA synthesis.
- 10 Glycocitrine-II (11) is a potent inhibitor of cell DNA synthesis, while its 3-methyl derivative (12) shows only moderate inhibitory activity.

Table 1. Inhibition of macromolecule biosynthesis and HL-60 cell growth by acridin-9-one derivatives



No.	Position										Molecular Weight	% Inhibition of Precursor Incorporation at 0.03 mg/mL			Cell Growth Inhibition, IC ₅₀ (mg/mL) (μM)	
	1	2	3	4	5	6	10	DNA	RNA	Protein		DNA	RNA	Protein	IC ₅₀ (mg/mL)	IC ₅₀ (μM)
4	OH		OH				H	227.26	76.7	50.6	62.8	0.0206	90.7			
5	OAC		OAC				H	311.34	39.7	24.9	26.9	>0.04	>129			
6	OAC		OAC				Me	325.36	23.0	2.7	-12.8	>0.04	>123			

Table 1 (cont'd)

No.	Position (R)							Molecular Weight	% Inhibition of Precursor Incorporation at 0.03 mg/ml			Cell Growth Inhibition, IC ₅₀ (mg/ml) (μ M)
	1	2	3	4	5	6	10		DNA	RNA	Protein	
<u>7</u>	1-Hydroxy-3-methoxy-N-methylacridone	OH		OMe			Me	255.30	48.4	39.5	25.2	>0.04 >157
<u>8</u>	1-Methoxy-3-Hydroxy-N-methylacridone	OMe	OH				Me	255.30	53.3	51.2	25.7	>0.04 >157
<u>9</u>	3-O-Acetyl-1-methoxy-R-methylacridone	OMe	OAC				Me	297.34	71.1	61.6	30.0	0.0305 102.6
<u>10</u>	1,3-Dimethoxy-N-methylacridone	OMe	OMe				Me	269.32	91.2	65.8	64.4	0.0092 34.2
<u>11</u>	Glyco-citrine-II	OH	OH	R			Me	309.38	99.5	97.1	95.3	0.0082 26.5

Table 1 (cont'd)

No.	Position (R)							Molecular Weight	% Inhibition of Precursor Incorporation at 0.03 mg/ml			Cell Growth Inhibition, IC ₅₀ (mg/ml) (μ M)
	1	2	3	4	5	6	10		DNA	RNA	Protein	
12 3-O-Meth-ylglyco-citrine-II	OH		OMe	R			Me	323.40	61.8	53.8	50.3	>0.04 >124
13 Glyco-citrine-I	H		OMe	R	OH		Me	339.40	97.5	43.9	41.1	0.0014 4.1
14 O-O-Di-acetyl-glycoci-trine-I.	OAC		OMe	R	OAC		Me	423.48	94.7	63.8	89.8	0.0056 13.2
15 Citrusi-nine-II	OH		OH	OMe	OH		Me	287.30	88.5	91.7	54.3	0.017 59.2
16 Citrusi-nine-I	OH		OMe	OMe	OH		Me	301.32	97.0	96.5	87.0	0.0026 8.6
17 5-O-Me-thylci-trusi-nine-I	OH		OMe	OMe	OMe		Me	315.34	93.4	96.4	93.0	0.0027 8.6
18 1,3,4,5-Tetra-methoxy-N-methylacridone	OMe		OMe	OMe	OMe		Me	329.36	91.5	57.0	71.8	0.0133 40.4

Table 1 (cont'd)

No.	Position (R)							Molecular Weight	% Inhibition of Precursor Incorporation at 0.03 mg/ml			Cell Growth Inhibition, IC ₅₀ (mg/ml) (μM)	
	1	2	3	4	5	6	10		DNA	RNA	Protein		
19 Grandi-sine-II	OH		OH		OMe	OMe	Me	301.32	76.5	96.0	27.3	>0.04	>133
20 O-Acetyl-grandisine-II	OH		OAc		OMe	OMe	Me	343.36	24.4	77.0	-5.6	0.0387	112.7
21 Grandi-sine-I	OH		OMe		OH	OMe	Me	301.32	71.7	69.5	22.8	>0.04	>133
22 Citpres-sine-I	OH		OMe		OMe	OMe	Me	301.32	65.0	80.9	90.5	>0.04	>133
23 Citpres-sine-II	OH		OMe		OMe	OMe	Me	315.34	34.8	95.0	28.3	>0.04	>127
24 1-O-Me-thyl-citpressine-II	OMe		OMe		OMe	OMe	Me	329.36	93.1	67.3	75.6	0.022	66.8
25 Buntanine	OH	R	OH		OMe	OH	Me	355.40	96.6	29.8	40.1	0.0036	10.1
26 N-Methyl-atalla-phylline	OH	R	OH	R	OH		Me	393.48	99.6	28.2	44.3	0.0054	13.7
27 Prenyl-citpres-sine	OH		OH	R	OMe	OH	Me	355.40	52.4	21.1	-15.7	0.036	94.5

31

Table 1 (cont'd)

No.	Position (R)						Molecular Weight	% Inhibition of Precursor Incorporation at 0.03 mg/ml			Cell Growth Inhibition, IC ₅₀ (mg/ml) (μM)
	1	2	3	4	5	6	10	DNA	RNA	Protein	
28 3,6-O,O-Diacetyl-prenyl-citpres-sine	OH		OAC	R	OMe	OAC	Me	96.8	96.1	89.6	0.0022 5.0
29 Grandi-sinine	OH		OMe	R	OMe	OH	Me	98.5	96.5	94.6	0.006 16.9 ³²
30 Balyu-mine-B	OH		OMe	R	OMe	OMe	Me	86.9	92.5	87.0	0.0017 4.4
31 Glyfo-line	OH	OMe	OMe	OMe	OMe	OH	Me	93.5	65.7	90.7	0.0004 1.1

Where R = -CH₂-CH=C(CH₃)₂


5 Compounds with penta-substituents split into two categories; those with substitution at position 4 (13-18) display excellent activity, whereas others possessing a substituent at position 6 (19-24) show relatively weaker activity. The only exception is compound 24 which inhibits 93% of DNA synthesis. In general, polysubstituted acridine-9-ones (25-31) inhibit DNA synthesis.

10

 In the series of acronycine derivatives (Table 2), 6-hydroxypyran[2,3-c]acridine-7-one (32) did not show good activity in this study, while the inhibitory activity of its O-methylated product (33) was markedly increased. Acronycine (1) was found to inhibit about 90% of prelabeled precursor incorporation into DNA, while poor activity for its disubstituted analogs (34-36) was observed. With the exception of compound 41 which has no substituent at C-11, trisubstituted acronycine derivatives (37-40) showed potent inhibitory effects on DNA synthesis.

15
20

Table 2. Inhibition of macromolecule biosynthesis and HL-60 cell growth by acronycine derivatives



No.	Position					Molecular Weight	% Inhibition of Precursor Incorporation at 0.03 mg/mL			Cell Growth Inhibition, IC ₅₀ (mg/mL) (μM)	
	5	6	10	11	12		DNA	RNA	Protein		
32 des-N-methyl-nor-acronycine		OH			H	293.36	69.2	77.5	85.9	0.0091	31.0
33 des-N-methyl-acronycine		OMe			H	307.38	93.8	67.3	86.4	0.0054	17.6
34 Atalaphyllidine		OH		OH	H	309.36	78.9	94.8	82.9	0.0013	4.2
35 Noracronycine		OH			Me	307.38	25.5	94.0	4.7	>0.04	>130
1 Acronycine		OMe			Me	293.36	91.4	21.3	25.4	0.0077	26.2
36 Severifoline	R	OH			H	361.46	20.0	ND	ND	>0.04	>111

Table 2 (cont'd)

No.	Position (R)				Molecular Weight	% Inhibition of Precursor Incorporation at 0.03 mg/ml			Cell Growth Inhibition, IC ₅₀ (mg/ml) (μM)
	5	6	10	11	12	DNA	RNA	Protein	
<u>37</u> 11-Hydroxy-noracronycine		OH		OH	Me	98.6	96.6	95.3	0.0023 7.1
<u>38</u> 1,2-Dihydro-11-hydroxy-noracronycine		OH		OH	Me	98.8	76.6	92.2	0.0055 16.9
<u>39</u> 11-methoxy-noracronycine		OMe		OMe	Me	98.9	39.9	36.2	0.0058 17.2
<u>40</u> Atalaphylline	R	OH		OH	H	98.8	24.4	41.8	0.0012 3.2
<u>41</u> N-Methylserifoline	R	OH			Me	21.3	-17.9	13.2	>0.04 >107
<u>42</u> Citraridone-I		OH	OH	OMe	Me	98.5	96.9	90.5	0.0029 8.2

Table 2 (cont'd)

No.	Position (R)					Molecular Weight	% Inhibition of Precursor Incorporation at 0.03 mg/ml			Cell Growth Inhibition, IC ₅₀ (mg/ml) (μM)
	5	6	10	11	12		DNA	RNA	Protein	
43 1,2-di-hydro-citra-cridone-I		OH	OH	OMe	Me	355.40	94.9	68.0	81.9	0.0064 18.0
44 Citra-cridone-II		OH	OMe	OMe	Me	367.42	77.6	96.4	62.7	>0.04 >109
45 6-O-Me-thylci-tracri-done-II		OMe	OMe	OMe	Me	381.44	98.7	37.8	49.8	0.0059 15.5
46 11-Hy-droxy-N-methyl-severi-foline	R	OH		OH	Me	391.48	97.9	16.7	4.22	0.0059 15.1
47 11-O-Acetyl-N-methyl-severifoline	R	OH		OAc	Me	433.52	58.4	16.2	36.2	0.0088 20.3

Where R = $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$

5 In comparing atalaphyllidine (34) with atalaphyllinine (40),
the latter showed greater activity. Thus, addition of a 3-
methyl-2-butenyl side-chain at the C-5 position of 34
10 results in increased activity. However, addition of this
side-chain at the same position in noracronycine (35) had no
effect on the inhibitory activity of 41. Compounds with
four substituents at 6, 10, 11 and 12 (42-45), and 5, 6, 11
and 12 (46) also exhibited significant activity. It should
15 also be noted here that 1,2-dihydro derivatives 38 and 43
were shown to have the same potency as their parent
compounds, 37 and 42, respectively.

Both derivatives of pyrano[3,2-b]acridine-6-one (48 and 49)
15 and their analog, cycloglycofoline (50) inhibited DNA
synthesis significantly, whereas furofoline derivative 51
and acridine dimer (52) were not active (Table 3).

-38-

Table 3. Inhibition of macromolecule biosynthesis and HL-60 cell growth by pyranofoline and furofoline derivatives

No.	Molecular Weight	% Inhibition of Precursor Incorporation at 0.03 mg/mL			Cell Growth Inhibition, IC ₅₀ (mg/mL) (μM)	
<u>48</u> Pyranofoline	353.40	98.8	97.2	96.4	0.0031	8.8
<u>49</u> Methoxymethyl-pyranofoline	397.44	85.3	70.1	87.3	0.0187	47.1
<u>50</u> Cycloglycofoline	391.48	98.7	55.7	92.1	0.0058	14.8
<u>51</u> Furofoline-II	322.38	13.1	-46.3	19.5	>0.04	>124.1
<u>52</u> Glycobismine-A	602.74	-27.8	-57.4	-13.2	>0.04	>66.4

Effect of Acridine Alkaloids on the Labeled Precursor Incorporation into RNA and Protein

5 HL-60 cells were incubated with [5-³H]Cyd or [2,3,4,5-³H]L-Leu in the presence and absence of alkaloids (0.03 mg/ml) in order to find the effects of the alkaloid on the incorporation of labeled precursors into RNA or protein. Most acridine alkaloids were found to have either a moderate
10 or low inhibitory effect on RNA and protein biosynthesis. Over 90% of RNA and protein biosynthesis were inhibited by compounds 11, 16, 17, 22, 28, 29 and 30 (Table 1). The same results were obtained from some derivatives of acronycine (Table 2) and pyranofoline derivative (50, Table 3). In
15 most cases, the amount required to inhibit precursor incorporation into DNA was less than that to inhibit precursor incorporation into RNA or protein (i.e. DNA synthesis is inhibited most potently).

20 Effect of Acridine Alkaloids on the Growth of Leukemic HL-60 Cells

The plant alkaloids were further examined for their effects on cell growth inhibition (Tables 1-3).

25 Compounds listed in Table 1 (acridin-9-one derivatives) with substituents at 1, 3 and 10 (4-9) and 1, 3, 5, 6 and 10 (19-24), in general, did not inhibit cell growth (with the exception of compound 10). Most compounds bearing
30 substituents at the 1, 3, 4, 5 and 10 positions (13-17, 26-31) showed significant inhibition. The most potent compound in this series was glyfoline (31) with an IC₅₀ of 0.0004 mg/ml (1.11 μM).

35 Cell growth inhibition by pyrano[2,3-c]acridine-7-one derivatives was compared to acronycine (1) (Chou, T.-C., et

al., Cancer Res. 43:3074-3079 (1983)) (Table 2). The simple 6-hydroxyl substituted derivatives (32, 35 and 44) only showed moderate cell growth inhibitory activity but their O-methylated counterparts (33, 1 and 45, respectively) were found to be significantly active. Atalaphyllidine (34) and its substituted 2-(3-methyl-2-butenyl) or N-methyl derivatives (40 and 37) were shown to have comparable activity. Severifoline (36) was reported to have no antitumor activity, but the antitumor activity was induced significantly by introduction of an OH group at position 11 (40). A similar trend was observed on several pairs of compounds (32 vs. 34; 35 vs. 37; 41 vs. 46). The 1,2-dihydro derivatives (38 and 43) were found to be only half as potent as their parent compounds (37 and 42, respectively). A linear isomer of acronycine, pyranofoline (48) (Table 3) and its analog cycloglycofoline exhibited better activity than that of acronycine. It is also interesting to note that, in general, there is a correlation between the potency of inhibiting precursor incorporation into DNA and the potency of inhibiting cell growth among these analogs. The correlation coefficient (r) for percent inhibition of DNA synthesis (x) vs log (IC₅₀ in mg/ml) for HL-60 cell growth (y) was r=0.54, whereas similar plots for RNA synthesis gave r=0.18 and for protein synthesis, r=0.43, (n=35). It appears that DNA synthesis is the major target for this group of compounds.

In summary, acronycine (1) has been shown to have a broad spectrum of antitumor activity against experimental neoplasms in laboratory animals (Table 4). In an attempt to search for more potent compounds and to determine structure-activity relationships, 50 acronycine-related acridine alkaloids were examined for their effects on inhibition of precursor incorporation into DNA, RNA and protein as well as their potency on inhibition of leukemic HL-60 cell growth.

Table 4. Experimental Tumor Spectrum of Acronycine (Svoboda et al.)

Tumor	Dose (ip, mg/kg/day)	Average weight change (g. T/C)	Average life span (days, T/C)	Percent activity
B82 leukemia	37.5 X 1 X 7	-1.4/+0.4	23.7/14.6	61
C1498 leukemia	28 X 1 X 10	-1.4/+0.8	31.5/17.6	79(7)
P1534 leukemia	30 X 1 X 10	-0.2/-0.7	16.5/18.2	0
L5178Y leukemia	28 X 1 X 10	+2.2/+3.2	24.2/15.0	62
AKR leukemia	28 X 1 X 10	+0.1/+0.8	38.3/21.5	78(5)
Ehrlich ascites	30 X 1 X 10	+5.6/+7.8	21.8/18.4	0(1)
Average tumor size (mm, T/C)				
Sarcoma 180	30 X 1 X 10	+3.2/+6.0	7.1/11.9	40(9)
Mecca lymphosarcoma	30 X 1 X 10	-0.4/+2.5	6.2/16.9	63(7)
Ridgeway osteogenic sarcoma	48 X 1 X 9	-0.6/+3.4	0/9.6	100(10)
X5563 myeloma	30 X 1 X 8	+0.1/+0.3	0/9.1	100(8)
Adrenocarcinoma 755	30 X 1 X 10	-0.5/+1.9	11.9/19.7	40(10)
Shionogi carcinoma 115	36 X 1 X 9	+1.4/+1.4	0/15.3	100(7)
S91 melanoma	36 X 1 X 9	-1.4/+0.1	0/14.1	100(4)

5 In general, derivatives of acronycine (pyrano[2,3-c]acridin-7-one) (Table 2) exhibited the most potent inhibition on the growth of leukemic HL-60 cells. It has also been found that acridin-9-one derivatives (Table 1) with substituents at the 1, 3, 4 and 10 positions (13, 14, 16, 17, 26, 28, 29 and 31) had significant activity against leukemic cells in vitro. There are structural similarities between these compounds and acronycine; the latter is considered as a 1, 3, 4 and 10 tetra-substituted acridin-9-one derivative. Accordingly, substituents at the above four positions of the acridin-9-one ring system may be essential for optimum biological activity.

15 The above structure-activity relationships may provide useful directions for future synthetic approaches to developing new antitumor chemotherapeutic agents.

20 **Summary of In Vivo Preliminary Studies on Acridones (Tables 5-7)**

A. L1210 Leukemia (Natural products used)

25 Compound 31 (SK-32889, TSA-35, glyfoline) showed some activity against L1210 leukemia in BDF mice at a low dose (12.5 mg/kg, starting day 1 for 4 days, i.p. injection)

30 Compound 34 (TSA-36) also showed evidence of antileukemic activity.

Compound 37 (TSA-7) and compound 17 (TSA-15) were not active.

35 B. Lewis Lung Carcinoma (Synthetic compounds used)

5 Compound 31 at 25 and 50 mg/kg daily for 4 days i.p. injection to C57BL/6 mice showed less toxicity to mice than that of compound 1 (acronycine, TSA-33, SK 32121). At 25 and 50 mg/kg, compound 31 increased life-span by 42% and >92%, respectively, whereas compound 1 increased life-span by 40% and 40%, respectively.

10 There were 2 out of 5 long-term survivals for 50 mg/kg for compound 31. Other groups had no long term survivals.

C. Carcinoma E07713 (Synthetic compounds used)

15 At 100 mg/kg daily for 4 days i.p. compound 1 showed 1 out of 3 toxicity induced deaths but no deaths were observed as a consequence of administration of compound 31.

20 At 50 mg/kg and 100 mg/kg, compound 31 increased life-span by 17% and >39%, respectively, whereas compound 1 increased life-span by 26% and 4% (although toxic), respectively.

Table 5. Survival Time Evaluation
 Tumor-Lewis Lung C. 3x10⁵ cells (ip) in C57BL/6, FEM, 19-21g
 Drug: A=SK 32121 TSA-acronycine
 B=SK 32089 TSA-35
 Diluent-CMC + 1 drop Tween 80 Schedule: Day 1, QDX4 (ip)

#	Dose MG/KG	Day #7 AWC (g)	Survival Time										AST ⁺	% ILS [*]	N/T
1	CONTROL	+0.1	10	10	10	10	10	10	10	10	10	10	10.4		0/10
2	Acronycin 50	-0.8	14	14	15	15	15						14.6	40	0/5
3	Acronycin 25	-0.6	14	14	14	14	17						14.6	40	0/5
4	TSA-35 50	+0.2	14	14	14	>29	>29						>20	>92	2/5
5	TSA-35 25	+0.2	14	14	14	14	18						14.8	42	0/5

44

* Increase in lifespan of 25% or greater indicates activity.
 Mice dying of toxicity (t) not included in AST evaluation.
 N/T = number of 29 day survivors/total mice.

Average weight change. Changes of less than 1 gm are not considered significant.
 Tumor may contribute to the body weight. Toxicity decreases body weight.

+ Average survival time.

Table 6. Survival Time Evaluation
 Tumor-Carcinoma EO771 3x10⁵ cells (ip) in C57BL/6, FEM, 19-21g
 Drug: A=SK 32121 TSA-acronycine
 B=SK 32089 TSA-35
 Diluent-CMC + 1 drop Tween 80 Schedule: Day 1, QDX4 (ip)

#	Dose MG/KG	Day #7 AWC (g)	Survival Time	AST ⁺	%ILS ⁺	N/T
1	CONTROL	+1.4	10 10 10 11 12	10.6		0/5
2	Acronycin 100	+0.5	4t 10 12	11.0	4	0/3
3	Acronycin 50	+0.4	11 11 14 14 17	13.4	26	0/5
4	TSA-35 100	+0.3	11 11 >22	>15	>39	1/3
5	TSA-35 50	+0.6	10 11 12 14 15	12.4	17	0/5

* Increase in lifespan of 25% or greater indicates activity.
 Mice dying of toxicity (t) not included in AST evaluation.
 N/T = number of 22 day survivors/total mice.

Average weight change. Changes of less than 1 gm are not considered significant. Tumor may contribute to the body weight. Toxicity decreases body weight.

+ Average survival time.

-46-

Table 7. Survival Time EvaluationTumor-L1210 10^6 cells (ip) in BDF1 (female) 19-21g

Drug: A=SK 32887 TSA-7

B=SK 32888 TSA-15

C=SK 32889 TSA-35

Diluent-DMSO, 0.05ml/m


Schedule: Day 1, QDX4 (ip)

#	Dose MG/KG	Day 6 AWC(g)	Survival Time	MST	%ILS*	N/T
1	Control (DMSO)	+2.6	7 7 7 7 7	7.0		0/5
2	SK 32887 6.25 11-Hydroxy-nor- acronycine (37) TSA-7	+2.0	7 7	7.0	0	0/2
3	SK 32887 25 11-Hydroxy-nor- acronycine (37) TSA-7	+1.8	7 7	7.0	0	0/2
4	SK 32888 6.25 5-O-Methyl- citrusinine-I (17) TSA-15	+1.8	7 7	7.0	0	0/2
5	SK 32888 12.5 5-O-Methyl- citrusinine-I (17) TSA-15	+1.5	7 7	7.0	0	0/2
6	SK 32889 6.25 Glyfoline (31) TSA-35	+1.8	7 7	7.0	0	0/2
7	SK 32889 12.5 Glyfoline (31) TSA-35	+2.0	8 8	8.0	14	0/2
1	SK 32090 6.25 Atalaphyllidine (34) TSA-36	+1.7	7 7	7.0	0	0/2
2	SK 32090 25. Atalaphyllidine (34) TSA-36	+1.5	7 8	7.5	7	0/2
3	SK 32091 12.5 Cycloglycofoline (50) TSA-48	+1.8	8 9	8.5	21	0/2

*Increase in lifespan of 25% or greater indicates activity.
Mice dying of toxicity (t) not included in MST evaluation.
N/T = Number of nine day survivors/total mice.

What is claimed is:

1. A method of inhibiting growth of tumor cells which comprises contacting the cells with a growth inhibiting amount of a compound having the structure:




wherein R¹ is a hydroxyl or acetyl group; R² is hydrogen, -CH₂-CH=C(CH₃)₂ or a methoxy group; R³ is a hydroxyl, methoxy or acetyl group; R⁴ is hydrogen, -CH₂-CH=C(CH₃)₂ or a methoxy group; R⁵ is a hydroxyl, methoxy or acetyl group; R⁶ is hydrogen or a hydroxyl, methoxy or acetyl group; and R¹⁰ is a methyl group.

2. A method of claim 1, wherein R¹ is an acetyl group; R² is hydrogen; R³ is a methoxy group; R⁴ is -CH₂-CH=C(CH₃)₂; R⁵ is an acetyl group; and R⁶ is hydrogen.
3. A method of claim 1, wherein R¹ is a hydroxyl group and R⁵ is a hydroxyl or a methoxy group.
4. A method of claim 3, wherein R² is hydrogen; R³ is a methoxy group; R⁴ is a methoxy group; R⁵ is a hydroxyl group; and R⁶ is hydrogen.
5. A method of claim 3, wherein R² is -CH₂-CH=C(CH₃)₂; R³ is a hydroxyl group; R⁴ is hydrogen; R⁵ is a methoxy group; and R⁶ is a hydroxyl group.
6. A method of claim 3, wherein R⁴ is -CH₂-CH=C(CH₃)₂ or a methoxy group.

7. A method of claim 6, wherein R^2 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^3 is a hydroxyl group; R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^5 is a hydroxyl group; and R^6 is hydrogen.
- 5 8. A method of claim 6, wherein R^2 is hydrogen or a methoxy group; and R^3 is a methoxy or acetyl group.
9. A method of claim 8, wherein R^2 , R^3 , R^4 and R^5 are methoxy groups; and R^6 is a hydroxyl group.
- 10 10. A method of claim 8, wherein R^2 is hydrogen.
11. A method of claim 10, wherein R^3 is a methoxy group; R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^5 is a hydroxyl group; and R^6 is hydrogen.
- 15 12. A method of claim 10, wherein R^5 is a methoxy group.
13. A method of claim 12, wherein R^3 is a methoxy group; R^4 is a methoxy group; and R^6 is hydrogen.
- 20 14. A method of claim 12, wherein R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; and R^6 is a hydroxyl, methoxy or acetyl group.
- 25 15. A method of claim 14, wherein R^3 and R^6 are methoxy groups.
16. A method of claim 14, wherein R^6 is a methoxy or acetyl group.
- 30 17. A method of claim 16, wherein R^3 is an acetyl group and R^4 is a methoxy group.
18. A method of claim 16, wherein R^3 and R^4 are methoxy groups.
- 35

19. A composition for inhibiting growth of tumor cells which comprises an amount of the compound having the structure:



wherein R^1 is a hydroxyl or acetyl group; R^2 is hydrogen, $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ or a methoxy group; R^3 is a hydroxyl, methoxy or acetyl group; R^4 is hydrogen, $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ or a methoxy group; R^5 is a hydroxyl, methoxy or acetyl group; R^6 is hydrogen or a hydroxyl, methoxy or acetyl group; and R^{10} is a methyl group;

effective to inhibit growth of tumor cells and a physiologically acceptable carrier.

20. A composition of claim 19, wherein R^1 is an acetyl group; R^2 is hydrogen; R^3 is a methoxy group; R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^5 is an acetyl group; and R^6 is hydrogen.

21. A composition of claim 19, wherein R^1 is a hydroxyl group and R^5 is a hydroxyl or a methoxy group.

22. A composition of claim 21, wherein R^2 is hydrogen; R^3 is a methoxy group; R^4 is a methoxy group; R^5 is a hydroxyl group; and R^6 is hydrogen.

23. A composition of claim 21, wherein R^2 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^3 is a hydroxyl group; R^4 is hydrogen; R^5 is a methoxy group; and R^6 is a hydroxyl group.

24. A composition of claim 21, wherein R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ or a methoxy group.

5 25. A composition of claim 24, wherein R^2 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^3 is a hydroxyl group; R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^5 is a hydroxyl group; and R^6 is hydrogen.

10 26. A composition of claim 24, wherein R^2 is hydrogen or a methoxy group; and R^3 is a methoxy or acetyl group.

27. A composition of claim 26, wherein R^2 , R^3 , R^4 and R^5 are methoxy groups; and R^6 is a hydroxyl group.

15 28. A composition of claim 26, wherein R^2 is hydrogen.

29. A composition of claim 28, wherein R^3 is a methoxy group; R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^5 is a hydroxyl group; and R^6 is hydrogen.

20 30. A composition of claim 28, wherein R^5 is a methoxy group.

25 31. A composition of claim 30, wherein R^3 is a methoxy group; R^4 is a methoxy group; and R^6 is hydrogen.

32. A composition of claim 30, wherein R^4 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; and R^6 is a hydroxyl, methoxy or acetyl group.

30 33. A composition of claim 32, wherein R^3 and R^6 are methoxy groups.

34. A composition of claim 32, wherein R^6 is a methoxy or acetyl group.

35 35. A composition of claim 34, wherein R^3 is an acetyl

group and R^4 is a methoxy group.


36. A composition of claim 34, wherein R^3 and R^4 are methoxy groups.

5

37. A composition of claim 19, wherein the compound comprises hydrophilic substituents to increase solubility.

10 38. A method of inhibiting growth of tumor cells which comprises contacting the cells with a growth inhibiting amount of a compound having the structure:

15



20

25 wherein R^5 is hydrogen or $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^6 is a hydroxyl group; R^{10} is hydrogen or a hydroxyl group; R^{11} is a hydroxyl or methoxy group; and R^{12} is hydrogen or a methyl group;

30 39. A method of claim 38, wherein R^5 is hydrogen; R^{10} is a hydroxyl group; R^{11} is a methoxy group; and R^{12} is a methyl group.

40. A method of claim 38, wherein R^{10} is a hydrogen; and R^{11} is a hydroxyl group.


35 41. A method of claim 40, wherein R^5 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ and R^{12} is hydrogen.

42. A method of claim 40, wherein R^5 is hydrogen.

43. A method of claim 42, wherein R^{12} is a methyl group.

5 44. A method of claim 42, wherein R^{12} is hydrogen.

45. A composition comprising an amount of a compound having the structure:



10
15 wherein R^5 is hydrogen or $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$; R^6 is a hydroxyl group; R^{10} is hydrogen or a hydroxyl group; R^{11} is a hydroxyl or methoxy group; and R^{12} is hydrogen or a methyl group;

effective to inhibit growth of tumor cells and a physiologically acceptable carrier.

20 46. A composition of claim 45, wherein R^5 is hydrogen; R^{10} is a hydroxyl group; R^{11} is a methoxy group; and R^{12} is a methyl group.

25 47. A composition of claim 45, wherein R^{10} is a hydrogen; and R^{11} is a hydroxyl group.

48. A composition of claim 47, wherein R^5 is $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$ and R^{12} is hydrogen.

30 49. A composition of claim 47, wherein R^5 is hydrogen.


50. A composition of claim 49, wherein R^{12} is a methyl group.

35 51. A composition of claim 49, wherein R^{12} is hydrogen.

52. A composition of claim 45, wherein the compound comprises hydrophilic substituents to increase solubility.

5 53. A method of inhibiting growth of tumor cells which comprises contacting the cells with a growth inhibiting amount of a compound having the structure:


10



15

54. A composition comprising an amount of a compound having the structure:

20



effective to inhibit growth of tumor cells and a physiologically acceptable carrier.


25

55. A composition of claim 54, wherein the compound comprises hydrophilic substituents to increase solubility.


30

56. A method of inhibiting growth of tumor cells which comprises contacting the cells with a growth inhibiting amount of a compound having the structure:

35



57. A composition comprising an amount of a compound having the structure:



- 10 effective to inhibit growth of tumor cells and a physiologically acceptable carrier.
58. A composition of claim 57, wherein the compound comprises hydrophilic substituents to increase solubility.
- 15

20

INTERNATIONAL SEARCH REPORT

International Application No PCT/US90/03065

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ³		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC (5): A01N 43/42 U.S. CL: 514/285,297		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System ¹	Classification Symbols	
U.S.	514/285,297	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁶		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category [*]	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
X	Chemical abstracts, volume 111, no. 14, issued 1989 (Columbus, Ohio, U.S.A.), H. Furukawa, "anticancer agents containing acridones", the abstract no. 120933 p, JP01040426A2 10 february 1989. (JP)	1-37
Y	Archivum immunologies Et Therapiae Experimentalis, volume 19, 1971, Radzikowski", A search for Antitumor compounds", pp 219-228	1-37
Y	Antiviral Research, volume 12, April 1989, Yamamoto, "Anti-herpesvirus activity of citrussinine-I, a new acridone alkaloid, and related compounds". pages 21-36	1-37
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ¹⁵</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ²	Date of Mailing of this International Search Report ³	
25 JUNE 1990	16 AUG 1990	
International Searching Authority ¹	Signature of Authorized Officer ¹⁹	
ISA/US	<div style="display: flex; align-items: center;"> <div style="text-align: center; margin-right: 10px;"> G.S. KISHORE </div> <div style="text-align: center;"> NGUYEN NGOC-HO INTERNATIONAL DIVISION </div> </div>	

Form PCT/ISA/210 (second sheet) (May 1986)

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter¹ not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out¹, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

Claims 1-37 are drawn to composition and method pertaining to species 1

Claims 38-52 are drawn to composition and method pertaining to species 2

Claims 53-55 are drawn to compositions and method pertaining to species 3

Claims 56-58 are drawn to compositions and method pertaining to species 4

The recited species are distinct invention which do not form a single inventive concept

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

1-37

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.

EUROPEAN PATENT OFFICE

Patent Abstracts of Japan

PUBLICATION NUMBER : 11199565

PUBLICATION DATE : 27-07-99

APPLICATION DATE : 16-10-98



APPLICATION NUMBER : 10294339

APPLICANT : TOYAMA CHEM CO LTD;

INVENTOR : SHIRAKI KIMIYASU;

INT.CL. : C07D219/06 A61K 31/00 A61K 31/435
A61K 31/44 A61K 31/47 A61K 31/495
A61K 31/505 A61K 31/535 A61K
31/535 A61K 31/70

TITLE : NITROGEN-CONTAINING TRI-OR
TETRACYCLIC COMPOUND AND
ANTIVIRAL AGENT CONTAINING THE
SAME COMPOUND



ABSTRACT : PROBLEM TO BE SOLVED: To obtain the subject medicine such as antiherpes viral agent exhibiting excellent antiviral activity and useful as a medicine by including a specific nitrogen-containing tri or tetracyclic compound.

SOLUTION: This antiviral agent contains a nitrogen-containing tri or tetracyclic compound of formula I [R^1 is a (substituted)alkyl or the like; R^2 is a (substituted)aryl or the like; R^3 is H or the like; R^4 is H or the like; A^1 or A^2 is N or the like; A^3 is CH or the like] or its salt [e.g. 2-fluoro-10- methyl-6-(pyridin-4-yl)-9,10-dihydro-9-acylidinone or the like]. The antiviral agent is administered at a daily dose of 0.1-100 mg/kg.adult once or in several portions. The compound of formula I is obtained by subjecting a compound of formula II (X is a leaving group) to coupling reaction with a tin compound of the formula $R^2-Sn(Alk)_3$ (Alk is a lower alkyl) in the presence (or absence) of silver oxide and in the presence of a palladium catalyst.

COPYRIGHT: (C)1999,JPO